Real-World GLP-1 RA Discontinuation Tied to Modest Weight Loss: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Delgocitinib, First Treatment for Adults With Moderate to Severe Chronic Hand Eczema
The nonsteroidal topical pan-JAK inhibitor provides a potent treatment option for adults with CHE who have not responded to corticosteroids or cannot tolerate them.
The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy
Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.
Refined Digital Tools Have Revolutionized the Return on Cognitive Screening: Investigator Rodney Swenson, PhD, Explains
Swenson focused on the precision afforded by digital tools in assessing human behavior and identifying preclinical signs of cognitive impairment.
Thimerosal to Be Eliminated from All US Vaccines, HHS Announces
HHS secretary Robert F Kennedy, Jr, today formally agreed with the recent ACIP recommendation to eliminate the already largely discontinued preservative.
Muscle Loss During GLP-1 Therapy Top Concern for Patients Using the Antiobesity Medications
Individuals on GLP-1 therapy express significant concern about muscle loss, prompting lifestyle changes and highlighting the need for informed primary care guidance.
Obesity and Cardiovascular Disease Management: 3 Pearls for Primary Care
Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.
Efficacy of Apnimed's Novel Oral Formulation Targeting OSA Confirmed in Second Phase 3 Trial
Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.
Cycling Tied to 19% Lower Risk of Dementia: Daily Dose
Obesity Is a Chronic Disease—Start the Conversation in Primary Care, Says Monu Khanna, MD
Dr Khanna discusses why obesity should be treated as a chronic disease in primary care and how early conversations can help prevent cardiometabolic complications.
What is Driving Type 2 Diabetes in the US?
Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.
AAIC 2025 to Feature Lecanemab Data on Long-Term Efficacy, Real-World Use, and Maintenance Dosing
Eisai will present four-year safety and efficacy data, real-world use patterns, and findings on a new subcutaneous formulation for maintenance treatment in early Alzheimer disease.
What is Precision Neurocognition? David J Libon, PhD, Provides an Overview
Libon, a professor at the New Jersey Institute for Successful Aging at Rowan University, says the refined approach to cognitive assessment is widely available.
World Brain Day 2025: 9 Studies on Alzheimer Disease and Related Dementias Chosen for Primary Care
World Brain Day is celebrated on July 22 every year. In recognition Patient Care has summarized 9 notable studies of key interest to primary care for quick review.
Monu Khanna, MD, on the Unique Role of Primary Care in Managing Cardiometabolic Disease
Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.
Needle-Free Epinephrine Nasal Spray Shows Promise in Pediatric Food Allergy Anaphylaxis
Neffy, a needle-free epinephrine nasal spray, showed promise as a safe alternative for treating anaphylaxis in children with food allergies in a phase 3 trial.
Atopic Dermatitis Flare Frequency May Predict Future Disease Severity, According to New Findings
Atopic dermatitis flares should be factored in to an assessment of disease severity and prognosis, the authors note, and a threshold established for acceptable frequency.
17 Vaccines for Adults: Who to Consider for Each
A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: health, age, lifestyle, and occupation (HALO).
Roche's Investigational Anti-IL-33/ST2 Antibody for COPD Misses Phase 3 Primary Endpoint
Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.
FDA Advisory Committee Casts Nearly Unanimous Vote Against Otsuka's PTSD Combination
The FDA advisory committee overwhelmingly voted against Otsuka's PTSD treatment, citing insufficient evidence from clinical trials for approval.
